Illumina Announces RapidTrack Whole Genome Sequencing Service
Other Sources for this Article
Illumina, Inc.
Investors:
Kevin Williams, MD
Investor
Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Jennifer
Temple
Public Relations
858-882-6822
pr@illumina.com
